Cara Therapeutics, Inc. clinical trials

Acquired by Tvardi Therapeutics, Inc., Apr 15, 2025 · source ↗

The registry lists 24 studies whose lead sponsor is Cara Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 21, 2024.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Tvardi Therapeutics, Inc. studies →

• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia ParestheticaTerminatedNCT05978063Phase 2/3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05356403Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05342623Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic DermatitisTerminatedNCT05387707Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusCompletedNCT03617536Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusTerminatedNCT03995212Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)CompletedNCT04706975Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis PatientsCompletedNCT05533008Phase 1

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinApproved for marketingNCT05031546

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03636269Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)CompletedNCT03422653Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisCompletedNCT04018027Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03998163Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03281538Phase 3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or KneeCompletedNCT02944448Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT02858726Phase 2/3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy SubjectsCompletedNCT04019574Phase 1

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy SubjectsCompletedNCT03947970Phase 1

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal SurgeryCompletedNCT02542384Phase 2/3

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or KneeCompletedNCT02524197Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic PruritusCompletedNCT02229929Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy SurgeryCompletedNCT00877799Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy SurgeryCompletedNCT01789476Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.

• Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy SurgeryCompletedNCT01361568Phase 2

  Sponsor listed in the registry: Cara Therapeutics, Inc. · First submitted before Cara Therapeutics, Inc. became part of Tvardi Therapeutics, Inc.